EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes

Nikhil Grandhi iD, Lawrence Liu iD, Mei Wang iD, Theodore Thomas, Martin Schoen iD, Kristen Sanfilippo, Feng Gao, Graham A Colditz iD, Kenneth R Carson iD, Murali Janakiram, Su-Hsin Chang iD

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Nikhil Grandhi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, St Louis VA Medical Center, St Louis, MO, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Disease Progression, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Siteman Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with diabetes and monoclonal gammopathy of uncertain significance (MGUS), the impact of glucagon-like peptide-1 (GLP-1) receptor agonists on the natural history of MGUS is unknown. We aimed to assess the association of GLP-1 receptor agonist use in the progression of MGUS to multiple myeloma in patients with diabetes.

Methods

This is a population-based cohort study of veterans diagnosed with MGUS from 2006 to 2021 with a prior diagnosis of diabetes. A validated natural language processing algorithm was used to confirm MGUS and progression to multiple myeloma. We performed 1:2 matching for individuals with and without GLP-1 receptor agonist exposure. The Gray test was performed to detect the difference in cumulative incidence functions for progression by GLP-1 receptor agonist use status. The association between time-varying GLP-1 receptor agonist use and progression was estimated through multivariable-adjusted hazard ratio using a stratified Fine-Gray distribution hazard model, with death as a competing event and stratum for the matched patient triad.

Results

Our matched cohort included 1097 individuals with MGUS who had ever used GLP-1 receptor agonists and the matched 2194 patients who had never used GLP-1 receptor agonists. Overall, 2.6% of individuals progressed in the GLP-1 receptor agonist ever use group compared with 5.0% in the GLP-1 receptor agonist never use group. Cumulative incidence functions were statistically significantly different between the exposed and unexposed groups (P = .02). GLP-1 receptor agonist use vs no use was associated with decreased progression to multiple myeloma (hazard ratio = 0.45, 95% confidence interval = 0.22 to 0.93, P = .03).

Conclusions

For patients with diabetes and MGUS, GLP-1 receptor agonist use is associated with a 55% reduction in risk of progression from MGUS to multiple myeloma compared with no use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceDisease ProgressionGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleAgedFemaleMiddle AgedCohort StudiesProportional Hazards ModelsIncidenceHypoglycemic AgentsDiabetes MellitusVeteransDiabetes Mellitus, Type 2

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Research Service, St Louis VA Medical Center, St Louis, MO, USA.
  • Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
  • Department of Medicine, Saint Louis University School of Medicine, St Louis, MO, USA.
  • Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

ORCID-Profile: Nikhil Grandhi, Lawrence Liu, Mei Wang, Martin Schoen, Graham A Colditz, Kenneth R Carson, Su-Hsin Chang

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Siteman Cancer Center
  • National Institutes of Health

Zitieren

APA

Grandhi, N., Liu, L., Wang, M., Thomas, T., Schoen, M., Sanfilippo, K., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., & Chang, S. H. (2024). Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae095

Vancouver

Grandhi N, Liu L, Wang M, Thomas T, Schoen M, Sanfilippo K, et al. Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae095

BibTeX
@article{Grandhi2024,
  author = {Grandhi, Nikhil and Liu, Lawrence and Wang, Mei and Thomas, Theodore and Schoen, Martin and Sanfilippo, Kristen and Gao, Feng and Colditz, Graham A and Carson, Kenneth R and Janakiram, Murali and Chang, Su-Hsin},
  title = {Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae095}
}
Kostenlos starten →